Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to Aflibercept
Condition: Neovascular Age-related Macular Degeneration Intervention: Drug: Brolucizumab 6 mg solution for intravitreal injection Sponsors: Vista Klinik; Novartis Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Age-Related Macular Degeneration (AMD) | Research